Market Newsdesk

• Expects Record Revenue: Exceeds $51 million for FY 2025, with Q4 revenue over $13 million and Adjusted EBITDA* above $500,000
• FY 2026 Guidance:
  • Revenues: $55-60 million
  • Adjusted EBITDA*: $2.5-4 million
• Industry Ranking: #9 on Podtrac for March 2025
• Kit Gray, President of PodcastOne, to present at Trump Mar-a-Lago today

LOS ANGELES, April 16, 2025 (GLOBE NEWSWIRE) — PodcastOne (NASDAQ: PODC), a leading publisher and podcast sales network, announced today that Kit Gray, President of PodcastOne, will present a business update and provide financial guidance to investors at Trump Mar-a-Lago today, Wednesday, April 16, 2025, as well as certain preliminary financial results for its fiscal year ended March 31, 2025 (“FY 2025”) and other updates.

PodcastOne’s full roster of top ranked podcasts includes programming across top genres such as news, comedy, true crime, sports and society and culture and includes shows such as The Jordan Harbinger Show, Karma and Chaos, Stassi, Off The Vine with Kaitlyn Bristowe, LadyGang, Cate & Ty Break it Down, The Prosecutors, Court Junkie, Cold Case Files, I Survived, and Varnamtown. PodcastOne shows are available through PodcastOne, Apple Podcasts, Spotify, YouTube, iHeart, Amazon and wherever podcasts are heard.

The select expected financial results discussed in this press release are based on management’s preliminary unaudited analysis of financial results for FY 2025. As of the date of this press release, PodcastOne has not completed its financial statement reporting process for FY 2025, and PodcastOne’s independent registered accounting firm has not audited the preliminary financial results discussed in this press release. During the course of PodcastOne’s fiscal year-end closing procedures and review process, PodcastOne may identify items that would require it to make adjustments, which may be material, to the information presented above. The estimated preliminary unaudited financial results contained in this press release are based only on currently available information as of the date hereof. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary financial results, and are not guarantees of future performance and may differ from actual results.

About PodcastOne

PodcastOne (NASDAQ: PODC) is a leading podcast platform that provides creators and advertisers with a comprehensive 360-degree solution in sales, marketing, public relations, production, and distribution. PodcastOne has surpassed 3.9 billion total downloads with a community of 200 top podcasters, including Adam Carolla, Kaitlyn Bristowe, Jordan Harbinger, LadyGang, A&E’s Cold Case Files, and Varnamtown. PodcastOne has built a distribution network reaching over 1 billion monthly impressions across all channels, including YouTube, Spotify, Apple Podcasts, and iHeartRadio. PodcastOne is also the parent company of PodcastOne Pro which offers fully customizable production packages for brands, professionals, or hobbyists. For more information, visit www.podcastone.com and follow us on Facebook, Instagram, YouTube, and X at @podcastone.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: LiveOne’s reliance on its largest OEM customer for a substantial percentage of its revenue; LiveOne’s and PodcastOne’s ability to consummate any proposed financing, acquisition, merger, distribution or other transaction, the timing of the consummation of any such proposed event, including the risks that a condition to the consummation of any such event would not be satisfied within the expected timeframe or at all, or that the consummation of any proposed financing, acquisition, merger, special dividend, distribution or transaction will not occur or whether any such event will enhance shareholder value; PodcastOne’s ability to continue as a going concern; PodcastOne’s ability to attract, maintain and increase the number of its listeners; PodcastOne identifying, acquiring, securing and developing content; LiveOne’s intent to repurchase shares of its and/or PodcastOne’s common stock from time to time under LiveOne’s announced stock repurchase program and the timing, price, and quantity of repurchases, if any, under the program; LiveOne’s ability to maintain compliance with certain financial and other covenants; PodcastOne successfully implementing its growth strategy, including relating to its technology platforms and applications; management’s relationships with industry stakeholders; LiveOne’s ability to extend and/or refinance its indebtedness and/or repay its indebtedness when due; uncertain and unfavorable outcomes in legal proceedings and/or PodcastOne’s and/or LiveOne’s ability to pay any amounts due in connection with any such legal proceedings; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of PodcastOne, LiveOne and/or LiveOne’s other subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in PodcastOne’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 1, 2024, PodcastOne’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2024, filed with the SEC on February 14, 2025, and in PodcastOne’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof, and PodcastOne disclaims any obligation to update these statements, except as may be required by law. PodcastOne intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

Use of Non-GAAP Financial Measures*

To supplement our consolidated financial statements, which are prepared and presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”), we present Contribution Margin (Loss) and Adjusted Earnings Before Interest Tax Depreciation and Amortization (“Adjusted EBITDA”), which are non-GAAP financial measures, as measures of our performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from, or as a substitute for, or superior to, operating loss and or net income (loss) or any other performance measures derived in accordance with GAAP or as an alternative to net cash provided by operating activities or any other measures of our cash flows or liquidity.

We use Contribution Margin (Loss) and Adjusted EBITDA to evaluate the performance of our operating segment. We believe that information about these non-GAAP financial measures assists investors by allowing them to evaluate changes in the operating results of our business separate from non-operational factors that affect operating income (loss) and net income (loss), thus providing insights into both operations and the other factors that affect reported results. Adjusted EBITDA is not calculated or presented in accordance with GAAP. A limitation of the use of Adjusted EBITDA as a performance measure is that it does not reflect the periodic costs of certain amortizing assets used in generating revenue in our business. Accordingly, Adjusted EBITDA should be considered in addition to, and not as a substitute for operating income (loss), net income (loss), and other measures of financial performance reported in accordance with GAAP. Furthermore, this measure may vary among other companies; thus, Adjusted EBITDA as presented herein may not be comparable to similarly titled measures of other companies.

Contribution Margin (Loss) is defined as Revenue less Cost of Sales. Adjusted EBITDA is defined as earnings before interest, other (income) expense, income tax expense, depreciation and amortization and before (a) non-cash GAAP purchase accounting adjustments for certain deferred revenue and costs, (b) legal, accounting and other professional fees directly attributable to acquisition activity, (c) employee severance payments and third party professional fees directly attributable to acquisition or corporate realignment activities, (d) certain non-recurring expenses associated with legal settlements or reserves for legal settlements in the period that pertain to historical matters that existed at acquired companies prior to their purchase date and a one-time minimum guarantee to effectively terminate a live events distribution agreement post COVID-19, and (e) certain stock-based compensation expense. Management does not consider these costs to be indicative of our core operating results.

With respect to projected full fiscal year 2025 and 2026 Adjusted EBITDA, a quantitative reconciliation is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to purchase accounting adjustments, acquisition-related charges and legal settlement reserves excluded from Adjusted EBITDA. We expect that the variability of these items to have a potentially unpredictable, and potentially significant, impact on our future GAAP financial results.

Press Contacts:

310.246.4600
[email protected]

IR Contact:

Chris Donovan
914-352-5853
[email protected]

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit” or the “Company“) today announced key leadership changes to support the company’s next phase of growth and execution.

Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will succeed Dr. David Tapolczay, who is stepping down as CEO and as a member of the Board of Directors for personal reasons. Dr. Tapolczay will continue to serve the company as Head of Strategy & Licensing, ensuring continuity in strategic development and with an immediate focus on out-licensing deals for its tapinarof patents.

Dr. Regan is a successful entrepreneur with an extensive background in founding and scaling innovative companies across sectors. At the age of 29, Dr. Regan sold Hobson Plc in 1996 for £154 million by way of a recommended cash takeover. In 2000, he was the founding shareholder of Asos plc, a global online fashion and beauty retailer which grew to a market capitalization in excess of £4.8 billion. Indian state-owned oil company ONGC Videsh acquired Imperial Energy, of which Dr. Regan was a founding shareholder, for £1.4 billion. In 2014, he was awarded a PhD for his research in writing and developing a bio-inspired algorithm for forecasting the financial markets. Dr. Regan brings deep business acumen and a proven ability to drive growth, scale operations, and unlock shareholder value—making him ideally suited to lead Conduit forward.

“We are grateful to David for his leadership during a pivotal time for Conduit,” said Dr. Regan. “He has laid the foundation for our future success and I am delighted that he will remain closely involved and can focus on out-licensing deals for the Company, given his excellent track-record of licensing and royalty deals in multiple pharmaceuticals products, including pembrolizumab, now marketed as Keytruda by Merck. We will maximise shareholder value at Conduit through licensing opportunities by creating new 20-year Composition-of-Matter patents, utilising cutting-edge AI and Cybernetics in collaboration with Sarborg to repurpose drugs, and by avoiding the operating inefficiencies of a traditional pharma company.”

Commenting on the transition, Dr. Tapolczay said, “It has been a privilege to serve as CEO of Conduit during this exciting phase of its evolution. I’m incredibly proud of what we have accomplished, from securing our public listing on NASDAQ to signing our license deal with AstraZeneca and advancing our pipeline towards our first clinical trial. Andrew’s entrepreneurial leadership and vision make him the right person to lead Conduit into the future, and I have full confidence in its growth under his guidance.”

The Company also announces that Faith Charles will be stepping down from the Board of Directors for personal reasons. Ms. Charles has been a key advisor and advocate for the Company during her tenure.

Chair of the Board of Directors, Dr. Freda Lewis-Hall, said, “We sincerely thank both David and Faith for their valuable contributions to Conduit’s early achievements. We welcome Andrew as CEO and are confident that under his leadership, Conduit will maximise value for patients, partners, and shareholders.”

About Conduit Pharmaceuticals

Conduit is a multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit’s future results of operations and financial position, Conduit’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under “Risk Factors” therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:

[email protected]

CORNELIUS, N.C., April 16, 2025 (GLOBE NEWSWIRE) —

Dear Shareholders,

Since our public debut through the successful completion of our DeSPAC transaction, Alpha Modus has remained unwavering in its mission to drive long-term shareholder value through the strategic advancement of our patent-protected, AI-powered retail technologies.

We are proud to report that in the months following our transition to a publicly traded company, we have consistently delivered on this mission:

• Filed New Infringement Actions: We have strategically initiated multiple patent infringement lawsuits targeting unauthorized use of our proprietary technologies by major players in retail and tech, reinforcing the strength and enforceability of our IP portfolio.
• Achieved First Major Settlement: We secured our first litigation settlement—validating our position, establishing a financial benchmark for future enforcement, and setting the stage for additional favorable outcomes.
• Expanded Our Patent Portfolio: We have broadened our IP footprint with new patent filings that strengthen and extend the scope of our core patents, particularly those underpinning dynamic, AI-powered retail engagement systems.
• Advanced Licensing and Sales Strategy: We are actively pursuing licensing deals with large retail and tech enterprises, creating a dual-channel revenue model—one driven by litigation outcomes, the other by commercial adoption.

Looking ahead, we are confident in our ability to generate substantial recurring revenue from both royalty-bearing settlements and enterprise technology licenses. These revenue streams are core to our long-term vision and are expected to grow as we continue to enforce our IP and scale our commercial efforts.

It is also important to contextualize our current valuation. Companies operating in the AI-driven retail technology space often trade at significantly higher multiples based on projected revenue, particularly when supported by strong IP and a forward-leaning commercial strategy. Given our progress, pipeline, and the precedents we’ve now established, we believe Alpha Modus is deeply undervalued relative to its true potential.

As we continue to release news around settlements, licenses, and new enforcement actions, we believe the market will begin to better recognize the intrinsic and future value of our company.

We thank you for your continued belief in our vision, and we remain resolute in our commitment to transforming this company into a category-defining leader—and a powerful vehicle for shareholder returns.

Sincerely,
William Alessi
Chief Executive Officer
Alpha Modus Holdings Inc.
(NASDAQ: AMOD)

Contacts:

Alpha Modus Holdings, Inc.
Investor Relations
[email protected]
+1 (704) 252-5050
Follow us on LinkedIn | Follow us on X

SINGAPORE, April 16, 2025 (GLOBE NEWSWIRE) — BrilliA Inc (NYSE American: BRIA) (“BrilliA” or “the Company”), a comprehensive one-stop service provider for ladies’ intimate apparel brands, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 1:30-2:00 PM PST. Kendrew Hartanto, CEO of BrilliA, will be hosting the presentation and answering questions at the conclusion.

To access the live presentation, please use the following information:

Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub

Date: Wednesday, April 23, 2025
Time: 1:30-2:00 PM (Las Vegas, NV Local Time PST)
Location: Track 5 – Concorde A
Webcast: https://event.summitcast.com/view/YNz6mnmEsXyrdRxb78w2nX/guest_book?session_id=aYWLZyvVsZxgMDhFeASonU

If you would like to book 1×1 investor meetings with BrilliA Inc, and to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please make sure you are registered here: REGISTER

1×1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV

The Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub website is available here: HOME PAGE

If you can’t make the live presentation, all company presentations “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”: AGENDA

About BrilliA Inc

BrilliA is a comprehensive one-stop service provider for ladies’ intimate apparel brands, managing sourcing, design, prototyping, supply chain, logistics, and quality control. The Company works with major global brands, including Fruit of the Loom, Hanes Brands Inc., and H&M.

About Planet MicroCap

Planet MicroCap is a global multimedia financial news, publishing and events company for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. federal securities laws. These statements include, but are not limited to, statements regarding BrilliA’s business strategy, market opportunities, future performance, and operational outlook. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to, global economic conditions, supply chain disruptions, customer demand, pricing pressures, and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission (SEC).

BrilliA undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law. BrilliA does not guarantee future results and undertakes no obligation to update these statements, except as required by law. Investors are encouraged to review BrilliA’s filings with the U.S. Securities and Exchange Commission (SEC) for additional risk factors.

For Further Information, Please Contact:

BrilliA Inc Contact:

220 Orchard Road, Unit 05-01, Midpoint Orchard
Singapore 238852
Phone: (+65) 6235 3388
Email: [email protected] 

Investor Relations Inquiries:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Phone: (646) 893-5835
Email: [email protected] 

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Vimeo, Inc. (NASDAQ: VMEO) today announced the date for its first quarter and fiscal year 2025 earnings report and earnings video event. After the close of market trading on Monday, May 5, 2025, Vimeo will post its results on the Investor Relations section of its website at https://www.vimeo.com/investors. On the same day, at 5:00 p.m. ET, Vimeo will livestream a video conference to answer questions. The live stream and replay of the video will be accessible to the public at https://www.vimeo.com/investors.

About Vimeo:

Vimeo (NASDAQ: VMEO) is the world’s most innovative video experience platform. We enable anyone to create high-quality video experiences to better connect and bring ideas to life. We proudly serve our community of millions of users – from creative storytellers to globally distributed teams at the world’s largest companies – whose videos receive billions of views each month. Learn more at www.vimeo.com.

Contact Us

Vimeo Investor Relations

[email protected]

Vimeo Communications

Ronda Morra
[email protected]

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes

Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company’s LIBERATE-1 clinical trial from which topline data is anticipated in mid-year 2025

ALAMEDA, Calif., April 16, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced its participation in a virtual fireside chat hosted by Yi Chen, Ph.D., CFA, Managing Director of Equity Research at H.C. Wainwright & Company.

As part of the presentation, Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D., will discuss Vivani’s LIBERATE-1 clinical trial. LIBERATE-1 is a first-in-human study of NPM-115, the Company’s miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management. Vivani anticipates topline data for LIBERATE-1 in mid-year 2025.

Details for viewing the fireside chat are as follows:

Date:	Thursday, April 24, 2025
Time:	10 a.m. Eastern Time
Weblink:	https://journey.ct.events/view/8202e32e-0026-417c-8e44-10a1503a831c

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal platform, Vivani develops therapeutic implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead programs, NPM-139 (semaglutide implant) and NPM-115 (exenatide implant), are miniature, subdermal GLP-1 implants under development for chronic weight management in obese or overweight individuals designed for once or twice-yearly administration. Vivani’s emerging pipeline also includes NPM-119, which refers to the Company’s six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a semaglutide implant for the treatment of type 2 diabetes is also under consideration. These NanoPortal implants are designed to provide patients with the opportunity to experience the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of oral and injectable medications.

Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason why obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature, ultra long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers. For more information, please visit: www.vivani.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 trial and reporting of trial results, Vivani’s emerging development plans for NPM-115, NPM-139, NPM-119, and Vivani’s technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani’s products, including NPM-115, NPM-139, and NPM-119; delays and changes in the development of Vivani’s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani’s development activities; risks related to the initiation, enrollment and conduct of Vivani’s planned clinical trials and the results therefrom; Vivani’s history of losses and Vivani’s ability to access additional capital or otherwise fund Vivani’s business; market conditions and the ability of Cortigent to complete its intended spin-off from the Company. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 31, 2025, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

Company Contact:
Donald Dwyer
Chief Business Officer
[email protected]
(415) 506-8462

Investor Relations Contact:
Jami Taylor
Investor Relations Advisor
[email protected]
(415) 506-8462

Media Contact:
Sean Leous
ICR Healthcare
[email protected]
(646) 866-4012

RESTON, Va., April 16, 2025 (GLOBE NEWSWIRE) — Comscore (Nasdaq: SCOR), a global leader in measuring and analyzing consumer behaviors, today announced a multi-season national and local TV measurement agreement with The Summit League, an NCAA Division I intercollegiate athletic conference with membership in the Midwestern United States. The Summit League will gain insights into viewer demographics, geographic reach, and engagement patterns through utilizing Comscore’s comprehensive measurement, enabling more targeted sponsorship and advertising strategies.

Featured on CBS Sports Network, The Summit League’s basketball games will now benefit from Comscore’s advanced big data science and methodology, delivering more granular and detailed insights than traditional measurement solutions.

As part of this agreement, Comscore will serve as a TV measurement provider for the 2024-2025 and 2025-2026 men’s and women’s basketball seasons, providing full visibility into the performance of the League’s televised games on both national networks and in local TV markets.

“Our multi-season partnership with The Summit League underscores Comscore’s commitment to delivering trusted, MRC-accredited national and local TV measurement data in 99% of all US zip codes,” said Steve Bagdasarian, Chief Commercial Officer at Comscore. “This deal reflects the growing demand for advanced audience measurement in sports broadcasting, particularly in the competitive landscape of college basketball viewership.”

“This partnership with Comscore allows us to take a data-driven approach in demonstrating the reach and impact of our basketball programs,” said Josh Fenton, Commissioner of The Summit League. “Having national and local TV measurement will be instrumental in showcasing the value of our broadcasts to sponsors while also helping us further elevate our conference and member institutions.”

“Our partnership with Comscore as the lead video measurement provider for Summit League basketball is a massive step forward in modernizing sports viewing analytics and is consistent with Commissioner Fenton always being on the cutting edge of media strategy and measurement,” said Ray Katz, Chief Operating Officer and Co-Founder of Collegiate Sports Management Group. “This deal unlocks new data and related revenue opportunities in college basketball sponsorship and media relationships and elevates The Summit League’s overall sponsorship potential.”

This marks Comscore’s first TV measurement agreement with an NCAA Division I intercollegiate athletic conference, further cementing Comscore’s leadership in the sports media measurement space. By expanding its presence in collegiate sports, Comscore is poised to offer unparalleled audience insights to conferences and teams nationwide.

About Comscore

Comscore is a global, trusted partner for planning, transacting, and evaluating media across platforms. With a robust data footprint that combines digital, linear TV, over-the-top, and theatrical viewership intelligence with advanced audience insights, Comscore empowers media buyers and sellers to quantify their multi-screen behavior and make meaningful business decisions with confidence. A proven leader in measuring digital and TV audiences and advertising at scale, Comscore is the industry’s emerging third-party source for reliable and comprehensive cross-platform measurement.

ABOUT THE SUMMIT LEAGUE

Headquartered in Sioux Falls, S.D., The Summit League is embarking on its 42nd year at the NCAA Division I level and offers 19 championship sports. The League’s nine institutions have a combined enrollment of nearly 100,000 and include five located in top 60 U.S. metropolitan populations and two land-grant universities. Full-time member institutions are the University of Denver, University of Missouri-Kansas City, University of North Dakota, North Dakota State University, University of Nebraska Omaha, Oral Roberts University, University of St. Thomas, University of South Dakota, and South Dakota State University.

Media Contact:

Marie Scoutas
Comscore
[email protected]

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Lotus Technology Inc. (“Lotus Tech” or the “Company”) (Nasdaq: LOT), a leading global intelligent and luxury mobility provider, today announced that Geely International (Hong Kong) Limited (“Geely”) exercised its put option on April 14, 2025, requiring us to purchase 51% of the equity interests in Lotus Advance Technologies Sdn Bhd (“Lotus UK”) held by Geely pursuant to the Put Option Agreement dated January 31, 2023 between the parties.

Lotus UK controls the manufacturing operations for Lotus’ sportscars and hyper cars, and Lotus Engineering which provides comprehensive consultancy services to many of the OEMs and Tier 1 suppliers around the world.

Pursuant to the exercise of put option from Geely, the Company expects to acquire 51% of the equity interest in Lotus UK through a non-cash transaction based on a pre-agreed pricing method¹. Upon completion, the Company will gain control over Lotus UK and consolidate its financial results. The strategic transaction will enable the Company to integrate all businesses under Lotus brand.

The acquisition is expected to be completed by 2025, subject to potential regulatory approvals.

In conjunction with the business combination between the Company and L Catterton Asia Acquisition Corp, a special purpose acquisition company affiliated with L Catterton, a leading global consumer-focused investment firm, the Company and Lotus UK entered into a Put Option Agreement with each of Geely and Etika. Pursuant to these agreements, each of Geely and Etika was granted the right to require the Company to acquire its equity interest in Lotus UK at a pre-agreed pricing method¹ and upon satisfaction of the condition (“Put Option Exercise Condition”) that the total number of vehicles sold by Lotus UK and its subsidiaries shall exceed 5,000 in 2024, with the exercise of such options by Geely and Etika not cross-conditioned on one another. As of December 31, 2024, the Put Option Exercise Condition had been satisfied.

Mr. Qingfeng Feng, Chief Executive Officers, said: “This acquisition marks a critical milestone in our strategic journey to fully integrate all businesses under the Lotus brand, which will strengthen brand equity and enhance our operational flexibility and internal synergies. We are confident that the transaction will create substantial long-term value for our shareholders.”

Note 1: Pursuant to the agreement, the Company will issue new shares valued at $10 per share in consideration of Geely and Etika’s transfer of Lotus UK shares. Lotus UK is valued at 1.15 multiples revenue plus cash minus debt of LGIL, based on LGIL’s audited consolidated annual financial report of 2024.

About Lotus Technology Inc.

Lotus Technology Inc. has operations across the UK, the EU and China. The Company is dedicated to delivering luxury lifestyle battery electric vehicles, with a focus on world-class R&D in next-generation automobility technologies such as electrification, digitalisation and more. For more information about Lotus Technology Inc., please visit www.group-lotus.com.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “forecast”, “plan”, “seek”, “future”, “propose” or “continue”, or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology. Forward-looking statements involve inherent risks and uncertainties, including those identified under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Lotus Tech undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Contact Information

For investor inquiries
[email protected]

Proven financial leader brings over 20 years of senior management experience navigating a multitude of public companies to fiscal responsibility and shareholder value creation 

WICHITA, Kan., April 16, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS) (“AgEagle” or the “Company”), a leading provider of best-in-class unmanned aerial systems (UAS) and sensors for military, public safety, and commercial use, announces the appointment of Alison Burgett, as Chief Financial Officer (CFO) of AgEagle, effective April 14, 2025. Ms. Burgett brings more than twenty years of financial, operational and regulatory experience with exchange listed companies and will be instrumental in helping guide the Company through its next phase of growth.

AgEagle CEO Bill Irby commented, “Alison has been a vital part of AgEagle’s leadership team in her role as Controller, where she has already demonstrated exceptional financial discipline, strategic insight, and a deep understanding of our business. Her promotion to CFO is a natural progression that reflects both her strong performance and the confidence we have in her ability to lead our financial strategy moving forward. As we continue to execute on our growth initiatives and expand our market presence, Alison’s leadership will be instrumental in driving operational efficiency, strengthening our financial infrastructure, and delivering long-term value to our shareholders.”

“With its cutting-edge technology, strong market position, and dedicated leadership team, AgEagle is uniquely positioned to drive meaningful innovation and expand its footprint in the rapidly growing drone technology sector,” said Ms. Burgett. “I look forward to leveraging my experience in corporate finance, strategic planning, and operational efficiency to support AgEagle’s long-term vision. By implementing sound financial strategies and fostering disciplined growth, we will further solidify AgEagle’s role as a leader in aerial intelligence solutions.”

Ms. Burgett has served as Controller of AgEagle since April 2024. In this capacity, she was responsible for overseeing the Company’s financial reporting, internal controls, budgeting, and compliance with regulatory standards, including SEC and GAAP requirements.

Prior to joining AgEagle, Ms. Burgett held key finance leadership roles over her tenure at Cente Corporation. Before joining Cente Corporation, Ms. Burgett held the position of Controller at Republic Services, Inc. and Director of Accounting at Providence Service Corporation where she supported strategic growth initiatives and implemented process improvements to enhance financial transparency and operational efficiency. She earned her undergraduate degree in Accounting from the University of Phoenix and her Master of Business Administration from Boise State University. Her expertise in corporate finance and regulatory compliance plays a vital role in supporting AgEagle’s financial integrity and long-term growth.

The Company wishes to thank Ms. Adrienne Anderson for her interim CFO services and contributions to AgEagle and wishes her success in her future endeavors.

About AgEagle Aerial Systems Inc.

Through its three Centers of Excellence, AgEagle is actively engaged in designing and delivering best-in-class flight hardware, sensors and software that solve important problems for its customers. Founded in 2010, AgEagle was originally formed to pioneer proprietary, professional-grade, fixed-winged drones and aerial imagery-based data collection and analytics solutions for the agriculture industry. Today, AgEagle is a leading provider of full stack UAS, sensors and software solutions for customers worldwide in the energy, construction, agriculture, and government verticals. For additional information, please visit our website at www.ageagle.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on AgEagle’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future purchase orders relating to AgEagle’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of AgEagle in general, see the risk disclosures in the Annual Report on Form 10-K of AgEagle for the year ended December 31, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by AgEagle. All such forward-looking statements speak only as of the date they are made, and AgEagle undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

AgEagle Aerial Systems Contacts

Investor Relations:

Email: [email protected]

Media:

Email: [email protected]

NANO Nuclear Aims to Expand Engineering and Project Development Team to Support U.S. and Canadian KRONOS MMR Energy System Reactor Construction and Licensing Efforts

New York, N.Y., April 16, 2025 (GLOBE NEWSWIRE) — Nano Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or the “Company”) is launching a recruitment initiative focused on the Midwest region to support its ambitious plans to construct, demonstrate and gain regulatory approval for full-scale KRONOS MMR Energy Systems in both the United States and Canada.

NANO Nuclear’s plans to extend its technical and project execution team are critical in the Company’s transition from design to ultimate commercial deployment of the proprietary, stationary KRONOS microreactor. In tandem with upcoming geological characterization work at the University of Illinois Urbana-Champaign (UIUC) site, this workforce build-out will consolidate the expertise and provide the personnel necessary to complete the construction permit application and begin construction of the first KRONOS prototype on the UIUC campus shortly thereafter.

Rendering of the KRONOS MMR

^TM

Energy System

“As we prepare to break ground on the KRONOS reactor prototype at UIUC, it’s time to scale our team to match our vision,” saidJames Walker, Chief Executive Officer of NANO Nuclear. “This is a call to the best and brightest in nuclear and energy innovation in the Midwest region—we’re building a reactor, and we need you on the team.”

Now Hiring Across All Core Disciplines

NANO Nuclear is actively recruiting top talent across a variety of critical disciplines for the KRONOS MMR project. Open positions include:

• Nuclear Engineers – Fuel & materials, reactor physics, thermal hydraulics, safety, and licensing
• Mechanical Engineers – design, structural, CAD, balance of plant
• Electrical Engineers – Instrumentation & control (I&C), power electronics, transmission
• Civil Engineers & Geotechnical Experts – Site layout, structural foundations, drilling operations
• Project Managers & Construction Specialists – Full-cycle oversight from permitting through commissioning
• QA/QC Professionals – Nuclear-grade standards, documentation, and supplier oversight
• Licensing & Regulatory Affairs Experts – NRC and CNSC compliance and filings
• Skilled Technicians – Fabrication, assembly, testing, and field support

Applicants with previous experience in nuclear R&D, DOE national labs, SMR or MMR programs, or international reactor development are especially encouraged to apply.

“Our collaboration with UIUC will be a critical operations hub for our KRONOS reactor development effort,” said Jay Yu, Founder, Chairman and President of NANO Nuclear. “It will house the growing team that’s building not only our U.S. research reactor, but also laying the foundation for our demonstration reactor deployment in Canada, which will open the path for eventual commercial rollout in both the U.S. and Canada.”

Canadian Reactor Construction Also in Focus

In parallel with the UIUC research reactor, Nano Nuclear is actively preparing to construct a KRONOS demonstration reactor in Canada, where it will enter the licensing process under Canadian Nuclear Safety Commission (CNSC) oversight. The effort will establish a second fully licensed KRONOS unit, positioning NANO Nuclear to efficiently move its microreactor technology through construction, demonstration, regulatory licensing and eventual commercialization across North America.

“Canada represents an incredible opportunity for clean, reliable microreactor deployment,” addedFlorent Heidet, Chief Technology Officer and Head of Reactor Development of NANO Nuclear. “By expanding our team and bringing additional talents onboard, we ensure we have the capacity to deliver simultaneous full-scale projects in two countries, each with independent regulatory pathways and future market potential.”

Join the Team Shaping the Future of Nuclear Energy

NANO Nuclear is a company that doesn’t just imagine the future—it’s engineering it, constructing it and moving towards regulatory licensing for it. With multiple microreactor project in progress, fuel qualification methodology already accepted by the NRC, and strategic partnerships underway, NANO Nuclear is one of the most active and ambitious advanced nuclear developers in the world.

“This recruitment drive is about finding those who want to be part of history,” saidJames Walker, Chief Executive Officer of NANO Nuclear. “If you want to help build the next generation of nuclear reactors from the ground up—this is your chance.”

How to Apply

Interested candidates can view open positions, including details regarding salary ranges and benefit offerings, and apply directly at:

https://nanonuclearenergy.com/careers

For inquiries, please contact:
Email:[email protected]
Business Tel: (212) 634-9206

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include patented KRONOS MMR^™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign (U. of I.), “ZEUS”, a solid core battery reactor, and “ODIN”, a low-pressure coolant reactor, and the space focused, portable LOKI MMR^™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR^™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon’s surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:

Email: [email protected]
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:

NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements

This news release and statements of NANO Nuclear’s management in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. In this press release, forward-looking statement relate to the NANO Nuclear’s recruitment drive and its development, demonstration, licensing and commercial plans, each as described herein. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy (“DOE”) or related state or non-U.S. nuclear fuel licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE, the Canadian Nuclear Safety Commission (CNSC) and the U.S. Nuclear Regulatory Commission (NRC), and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Attachment

• NANO Nuclear Energy Inc.